PDE4 News and Research

RSS
FDA approved PDE4 inhibitor roflumilast for atopic dermatitis

FDA approved PDE4 inhibitor roflumilast for atopic dermatitis

Ginger shows promise as a natural defense against autoimmune diseases

Ginger shows promise as a natural defense against autoimmune diseases

Salk professor receives $1.2 million from Larry L. Hillblom Foundation for diabetes research

Salk professor receives $1.2 million from Larry L. Hillblom Foundation for diabetes research

HSS study provides insight into real-world medication use for treatment of psoriatic arthritis

HSS study provides insight into real-world medication use for treatment of psoriatic arthritis

Drugs targeting neutrophils could reduce ARDS in severe COVID-19

Drugs targeting neutrophils could reduce ARDS in severe COVID-19

EULAR publishes updated recommendations for treating people with psoriatic arthritis

EULAR publishes updated recommendations for treating people with psoriatic arthritis

Resveratrol shows promise for anxiety and depression

Resveratrol shows promise for anxiety and depression

Plant compound found in red wine displays anti-stress effects

Plant compound found in red wine displays anti-stress effects

Scientists develop new class of drugs to treat hereditary kidney disease

Scientists develop new class of drugs to treat hereditary kidney disease

Tetra begins human Phase 1 safety trials of BPN14770

Tetra begins human Phase 1 safety trials of BPN14770

Study reveals potential new therapeutic target for depression treatment

Study reveals potential new therapeutic target for depression treatment

Study explains why COPD patients develop tolerance to roflumilast drug

Study explains why COPD patients develop tolerance to roflumilast drug

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Scientists develop new drug to treat obstructive airway diseases

Scientists develop new drug to treat obstructive airway diseases

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.